Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(25%)
Results Posted
150%(3 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_3
2
50%
Ph phase_1
1
25%
Ph phase_2
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)

Trials by Status

terminated125%
active_not_recruiting125%
completed250%

Recent Activity

1 active trials
Showing 4 of 4
active_not_recruitingphase_3

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

NCT03568383
terminatedphase_2

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

NCT04272242
completedphase_3

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

NCT01404312
completedphase_1

Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women

NCT02651259

Clinical Trials (4)

Showing 4 of 4 trials
NCT03568383Phase 3

Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients

Active Not Recruiting
NCT04272242Phase 2

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

Terminated
NCT01404312Phase 3

Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)

Completed
NCT02651259Phase 1

Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women

Completed

All 4 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
4